Capmatinib (Tabrecta) is a type of MET inhibitor that has shown promising results in the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as MET exon 14 skipping. In a clinical trial, researchers evaluated the effectiveness of capmatinib in both treatment-naïve and previously treated patients with this type of NSCLC.
The study found that among treatment-naïve patients, the objective response rate (ORR) was 68%, meaning that nearly 7 out of 10 patients had a significant reduction in their tumor size. The duration of response (DOR) was 16.6 months, which indicates that the response lasted for an average of 16.6 months before the disease progressed again.
Among previously treated patients, the ORR was slightly lower at 44%, indicating that the drug was still effective in reducing tumor size in nearly half of the patients. The DOR was 9.7 months, which is slightly shorter than in treatment-naïve patients, but still significant.
Overall, these results suggest that capmatinib has the potential to be an effective treatment option for patients with NSCLC that has the MET exon 14 skipping mutation, whether they have been previously treated or not.
Tepotinib (Tepmetko) is another MET inhibitor that has shown promise in the treatment of non-small cell lung cancer (NSCLC) with the MET exon 14 skipping mutation. The VISION trial was a phase 2 study that evaluated the efficacy and safety of tepotinib in patients with advanced NSCLC who had this specific genetic mutation.
The study found that the objective response rate (ORR) by independent review was 46%, indicating that almost half of the patients had a significant reduction in tumor size. The median duration of response was 11.1 months, meaning that the response lasted for an average of 11.1 months before the disease progressed again.
Comparing the results of Capmatinib and Tepotinib in clinical trials:
| Drug | Study | ORR | Median DOR |
|---|---|---|---|
| Capmatinib | Treatment-naïve | 68% | 16.6 months |
| Previously-treated | 44% | 9.7 months | |
| Tepotinib | VISION trial | 46% | 11.1 months |
Overall, both Capmatinib and Tepotinib have shown promise as treatments for NSCLC with the MET exon 14 skipping mutation, with high objective response rates and significant median durations of response. However, it is important to note that these drugs can have different side effects and may be better suited for different patient populations, so individualized treatment plans should always be developed in consultation with a medical professional.
